Global Antiretroviral Therapy
Global Antiretroviral Therapy

Antiretroviral Therapy Comprehensive Study by Route of Administration (Oral, Parenteral), Class (Nucleoside Reverse Transcriptase Inhibitors, HIV Protease Inhibitors, Non-nucleoside Reverse Transcriptase Inhibitors, Nucleotide Reverse Transcriptase Inhibitors, HIV Fusion Inhibitors), End User (Hospitals, Specialty Clinics, Others) Players and Region - Global Market Outlook to 2026

Antiretroviral Therapy Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Oct 2021 Edition 235 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Antiretroviral Therapy Market Overview:
Anti-retroviral therapies are used to treat infections caused by retroviruses, most often HIV. A retrovirus is a type of virus that belongs to the Retroviridae family and carries its genetic blueprint in the form of ribonucleic acid (RNA). Anti-retroviral medications work by preventing these viruses from multiplying rather than killing them. Growing cases of sexually transmitted diseases drive the antiretroviral therapy market.

Growth Drivers
  • Rising Burden of HIV
  • Growing Cases of Sexually Transmitted Diseases

Roadblocks
  • Side Effects of Drugs

Opportunities
  • Easy Availability of Diagnosis Tests Treatments
  • Patient’s Awareness regarding Diseases and Treatment in Developing Countries

Challenges
  • Stringent FDA Guidelines for Approval and Commercialization of New Drugs


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Gilead Sciences, Inc. (United States), F. Hoffmann-La Roche (Switzerland), ViiV Healthcare (United States), Boehringer Ingelheim (Germany), Janssen Pharmaceuticals (Belgium), Mylan (United States), Abbvie (United States), Bionor Pharma (Norway) and Vertex Pharmaceuticals (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Antiretroviral Therapy market by 2026. Considering Market by Route of Administration, the sub-segment i.e. Oral will boost the Antiretroviral Therapy market. Considering Market by Class, the sub-segment i.e. Nucleoside Reverse Transcriptase Inhibitors will boost the Antiretroviral Therapy market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Antiretroviral Therapy market.

Latest Market Insights:
On Apr 29, 2021, ImmunityBio, Inc. announced that the U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research has launched a Phase 2 clinical trial in Thailand to evaluate ImmunityBio’s interleukin-15 (IL-15) superagonist Anktiva® (also called N-803) administered in combination with antiretroviral therapy (ART) during acute HIV infection as an experimental therapy to target and inhibit early establishment of HIV ‘reservoirs’ in infected individuals.

On July 02, 2020, U.S. Food and Drug Administration approved Rukobia (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies because of resistance, intolerance or safety considerations.

What Can be Explored with the Antiretroviral Therapy Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Antiretroviral Therapy Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Antiretroviral Therapy
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Antiretroviral Therapy market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Antiretroviral Therapy market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants and Investors, Antiretroviral Therapy Provider, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Antiretroviral Therapy Market?
The Antiretroviral Therapy market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Antiretroviral Therapy Market?
Top performing companies in the Global Antiretroviral Therapy market are Gilead Sciences, Inc. (United States), F. Hoffmann-La Roche (Switzerland), ViiV Healthcare (United States), Boehringer Ingelheim (Germany), Janssen Pharmaceuticals (Belgium), Mylan (United States), Abbvie (United States), Bionor Pharma (Norway) and Vertex Pharmaceuticals (United States), to name a few.

3. What trending factors would impact Antiretroviral Therapy Market growth most?
"Increasing Investment in R&D" is seen as one of major influencing trends for Antiretroviral Therapy Market during projected period 2020-2026.

Report Objectives / Segmentation Covered
By Route of Administration
  • Oral
  • Parenteral

By Class
  • Nucleoside Reverse Transcriptase Inhibitors
  • HIV Protease Inhibitors
  • Non-nucleoside Reverse Transcriptase Inhibitors
  • Nucleotide Reverse Transcriptase Inhibitors
  • HIV Fusion Inhibitors

By End User
  • Hospitals
  • Specialty Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Burden of HIV
      • 3.2.2. Growing Cases of Sexually Transmitted Diseases
    • 3.3. Market Challenges
      • 3.3.1. Stringent FDA Guidelines for Approval and Commercialization of New Drugs
    • 3.4. Market Trends
      • 3.4.1. Increasing Investment in R&D
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Antiretroviral Therapy, by Route of Administration, Class, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Antiretroviral Therapy (Value)
      • 5.2.1. Global Antiretroviral Therapy by: Route of Administration (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Parenteral
      • 5.2.2. Global Antiretroviral Therapy by: Class (Value)
        • 5.2.2.1. Nucleoside Reverse Transcriptase Inhibitors
        • 5.2.2.2. HIV Protease Inhibitors
        • 5.2.2.3. Non-nucleoside Reverse Transcriptase Inhibitors
        • 5.2.2.4. Nucleotide Reverse Transcriptase Inhibitors
        • 5.2.2.5. HIV Fusion Inhibitors
      • 5.2.3. Global Antiretroviral Therapy by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Specialty Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Antiretroviral Therapy Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Antiretroviral Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Gilead Sciences, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. ViiV Healthcare (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Boehringer Ingelheim (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Janssen Pharmaceuticals (Belgium)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mylan (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abbvie (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bionor Pharma (Norway)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Vertex Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Antiretroviral Therapy Sale, by Route of Administration, Class, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Antiretroviral Therapy (Value)
      • 7.2.1. Global Antiretroviral Therapy by: Route of Administration (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Parenteral
      • 7.2.2. Global Antiretroviral Therapy by: Class (Value)
        • 7.2.2.1. Nucleoside Reverse Transcriptase Inhibitors
        • 7.2.2.2. HIV Protease Inhibitors
        • 7.2.2.3. Non-nucleoside Reverse Transcriptase Inhibitors
        • 7.2.2.4. Nucleotide Reverse Transcriptase Inhibitors
        • 7.2.2.5. HIV Fusion Inhibitors
      • 7.2.3. Global Antiretroviral Therapy by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Specialty Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Antiretroviral Therapy Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Antiretroviral Therapy: by Route of Administration(USD Million)
  • Table 2. Antiretroviral Therapy Oral , by Region USD Million (2015-2020)
  • Table 3. Antiretroviral Therapy Parenteral , by Region USD Million (2015-2020)
  • Table 4. Antiretroviral Therapy: by Class(USD Million)
  • Table 5. Antiretroviral Therapy Nucleoside Reverse Transcriptase Inhibitors , by Region USD Million (2015-2020)
  • Table 6. Antiretroviral Therapy HIV Protease Inhibitors , by Region USD Million (2015-2020)
  • Table 7. Antiretroviral Therapy Non-nucleoside Reverse Transcriptase Inhibitors , by Region USD Million (2015-2020)
  • Table 8. Antiretroviral Therapy Nucleotide Reverse Transcriptase Inhibitors , by Region USD Million (2015-2020)
  • Table 9. Antiretroviral Therapy HIV Fusion Inhibitors , by Region USD Million (2015-2020)
  • Table 10. Antiretroviral Therapy: by End User(USD Million)
  • Table 11. Antiretroviral Therapy Hospitals , by Region USD Million (2015-2020)
  • Table 12. Antiretroviral Therapy Specialty Clinics , by Region USD Million (2015-2020)
  • Table 13. Antiretroviral Therapy Others , by Region USD Million (2015-2020)
  • Table 14. South America Antiretroviral Therapy, by Country USD Million (2015-2020)
  • Table 15. South America Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 16. South America Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 17. South America Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 18. Brazil Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 19. Brazil Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 20. Brazil Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 21. Argentina Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 22. Argentina Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 23. Argentina Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 24. Rest of South America Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 25. Rest of South America Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 26. Rest of South America Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 27. Asia Pacific Antiretroviral Therapy, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 29. Asia Pacific Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 30. Asia Pacific Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 31. China Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 32. China Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 33. China Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 34. Japan Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 35. Japan Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 36. Japan Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 37. India Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 38. India Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 39. India Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 40. South Korea Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 41. South Korea Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 42. South Korea Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 43. Taiwan Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 44. Taiwan Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 45. Taiwan Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 46. Australia Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 47. Australia Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 48. Australia Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 52. Europe Antiretroviral Therapy, by Country USD Million (2015-2020)
  • Table 53. Europe Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 54. Europe Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 55. Europe Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 56. Germany Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 57. Germany Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 58. Germany Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 59. France Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 60. France Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 61. France Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 62. Italy Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 63. Italy Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 64. Italy Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 65. United Kingdom Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 66. United Kingdom Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 67. United Kingdom Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 68. Netherlands Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 69. Netherlands Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 70. Netherlands Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 71. Rest of Europe Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 72. Rest of Europe Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 73. Rest of Europe Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 74. MEA Antiretroviral Therapy, by Country USD Million (2015-2020)
  • Table 75. MEA Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 76. MEA Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 77. MEA Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 78. Middle East Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 79. Middle East Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 80. Middle East Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 81. Africa Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 82. Africa Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 83. Africa Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 84. North America Antiretroviral Therapy, by Country USD Million (2015-2020)
  • Table 85. North America Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 86. North America Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 87. North America Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 88. United States Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 89. United States Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 90. United States Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 91. Canada Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 92. Canada Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 93. Canada Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 94. Mexico Antiretroviral Therapy, by Route of Administration USD Million (2015-2020)
  • Table 95. Mexico Antiretroviral Therapy, by Class USD Million (2015-2020)
  • Table 96. Mexico Antiretroviral Therapy, by End User USD Million (2015-2020)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Antiretroviral Therapy: by Route of Administration(USD Million)
  • Table 107. Antiretroviral Therapy Oral , by Region USD Million (2021-2026)
  • Table 108. Antiretroviral Therapy Parenteral , by Region USD Million (2021-2026)
  • Table 109. Antiretroviral Therapy: by Class(USD Million)
  • Table 110. Antiretroviral Therapy Nucleoside Reverse Transcriptase Inhibitors , by Region USD Million (2021-2026)
  • Table 111. Antiretroviral Therapy HIV Protease Inhibitors , by Region USD Million (2021-2026)
  • Table 112. Antiretroviral Therapy Non-nucleoside Reverse Transcriptase Inhibitors , by Region USD Million (2021-2026)
  • Table 113. Antiretroviral Therapy Nucleotide Reverse Transcriptase Inhibitors , by Region USD Million (2021-2026)
  • Table 114. Antiretroviral Therapy HIV Fusion Inhibitors , by Region USD Million (2021-2026)
  • Table 115. Antiretroviral Therapy: by End User(USD Million)
  • Table 116. Antiretroviral Therapy Hospitals , by Region USD Million (2021-2026)
  • Table 117. Antiretroviral Therapy Specialty Clinics , by Region USD Million (2021-2026)
  • Table 118. Antiretroviral Therapy Others , by Region USD Million (2021-2026)
  • Table 119. South America Antiretroviral Therapy, by Country USD Million (2021-2026)
  • Table 120. South America Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 121. South America Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 122. South America Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 123. Brazil Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 124. Brazil Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 125. Brazil Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 126. Argentina Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 127. Argentina Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 128. Argentina Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 129. Rest of South America Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 130. Rest of South America Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 131. Rest of South America Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 132. Asia Pacific Antiretroviral Therapy, by Country USD Million (2021-2026)
  • Table 133. Asia Pacific Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 134. Asia Pacific Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 135. Asia Pacific Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 136. China Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 137. China Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 138. China Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 139. Japan Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 140. Japan Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 141. Japan Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 142. India Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 143. India Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 144. India Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 145. South Korea Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 146. South Korea Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 147. South Korea Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 148. Taiwan Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 149. Taiwan Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 150. Taiwan Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 151. Australia Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 152. Australia Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 153. Australia Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 154. Rest of Asia-Pacific Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 157. Europe Antiretroviral Therapy, by Country USD Million (2021-2026)
  • Table 158. Europe Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 159. Europe Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 160. Europe Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 161. Germany Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 162. Germany Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 163. Germany Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 164. France Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 165. France Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 166. France Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 167. Italy Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 168. Italy Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 169. Italy Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 170. United Kingdom Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 171. United Kingdom Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 172. United Kingdom Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 173. Netherlands Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 174. Netherlands Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 175. Netherlands Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 176. Rest of Europe Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 177. Rest of Europe Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 178. Rest of Europe Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 179. MEA Antiretroviral Therapy, by Country USD Million (2021-2026)
  • Table 180. MEA Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 181. MEA Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 182. MEA Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 183. Middle East Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 184. Middle East Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 185. Middle East Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 186. Africa Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 187. Africa Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 188. Africa Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 189. North America Antiretroviral Therapy, by Country USD Million (2021-2026)
  • Table 190. North America Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 191. North America Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 192. North America Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 193. United States Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 194. United States Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 195. United States Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 196. Canada Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 197. Canada Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 198. Canada Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 199. Mexico Antiretroviral Therapy, by Route of Administration USD Million (2021-2026)
  • Table 200. Mexico Antiretroviral Therapy, by Class USD Million (2021-2026)
  • Table 201. Mexico Antiretroviral Therapy, by End User USD Million (2021-2026)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Antiretroviral Therapy: by Route of Administration USD Million (2015-2020)
  • Figure 5. Global Antiretroviral Therapy: by Class USD Million (2015-2020)
  • Figure 6. Global Antiretroviral Therapy: by End User USD Million (2015-2020)
  • Figure 7. South America Antiretroviral Therapy Share (%), by Country
  • Figure 8. Asia Pacific Antiretroviral Therapy Share (%), by Country
  • Figure 9. Europe Antiretroviral Therapy Share (%), by Country
  • Figure 10. MEA Antiretroviral Therapy Share (%), by Country
  • Figure 11. North America Antiretroviral Therapy Share (%), by Country
  • Figure 12. Global Antiretroviral Therapy share by Players 2020 (%)
  • Figure 13. Global Antiretroviral Therapy share by Players (Top 3) 2020(%)
  • Figure 14. Global Antiretroviral Therapy share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Gilead Sciences, Inc. (United States) Revenue: by Geography 2020
  • Figure 18. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2020
  • Figure 20. ViiV Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 21. ViiV Healthcare (United States) Revenue: by Geography 2020
  • Figure 22. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 24. Janssen Pharmaceuticals (Belgium) Revenue, Net Income and Gross profit
  • Figure 25. Janssen Pharmaceuticals (Belgium) Revenue: by Geography 2020
  • Figure 26. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 27. Mylan (United States) Revenue: by Geography 2020
  • Figure 28. Abbvie (United States) Revenue, Net Income and Gross profit
  • Figure 29. Abbvie (United States) Revenue: by Geography 2020
  • Figure 30. Bionor Pharma (Norway) Revenue, Net Income and Gross profit
  • Figure 31. Bionor Pharma (Norway) Revenue: by Geography 2020
  • Figure 32. Vertex Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 33. Vertex Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 34. Global Antiretroviral Therapy: by Route of Administration USD Million (2021-2026)
  • Figure 35. Global Antiretroviral Therapy: by Class USD Million (2021-2026)
  • Figure 36. Global Antiretroviral Therapy: by End User USD Million (2021-2026)
  • Figure 37. South America Antiretroviral Therapy Share (%), by Country
  • Figure 38. Asia Pacific Antiretroviral Therapy Share (%), by Country
  • Figure 39. Europe Antiretroviral Therapy Share (%), by Country
  • Figure 40. MEA Antiretroviral Therapy Share (%), by Country
  • Figure 41. North America Antiretroviral Therapy Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Gilead Sciences, Inc. (United States)
  • F. Hoffmann-La Roche (Switzerland)
  • ViiV Healthcare (United States)
  • Boehringer Ingelheim (Germany)
  • Janssen Pharmaceuticals (Belgium)
  • Mylan (United States)
  • Abbvie (United States)
  • Bionor Pharma (Norway)
  • Vertex Pharmaceuticals (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation